$0.00
Shopping Cart
Facebook-f Instagram
DONATE
Donate

Clinical Trial Record

Return to Clinical Trials

Influence Factors of PD-1 Therapeutic Efficacy in Advanced Pancreatic Cancer

2021-08-01

2022-12-31

2022-12-31

30

Study Overview

Influence Factors of PD-1 Therapeutic Efficacy in Advanced Pancreatic Cancer

The early diagnosis rate of pancreatic cancer is low and most patients rely on palliative chemotherapy. However, the clinical benefit and objective response rate (ORR) of patients with first-line chemotherapy are low. Therefore,it is essential to develop new therapies to improve the survival of patients with pancreatic cancer.

In this study, patients with advanced pancreatic cancer who failed in the first-line chemotherapy will be included to receive anti-PD-1 monoclonal antibody treatment, and a high-throughput study with a small sample size will be carried out by using multiomics technology to capture the heterogeneity of response to PD-1 therapy in patients with pancreatic cancer.The investigators choose two time points: after chemotherapy failure (before PD-1 therapy) and during efficacy evaluation（after PD-1 therapy）, to obtain in situ samples of pancreatic cancer tissues by EUS-FNA.The samples are tested by dynamic multi-omics studybefore and after treatment (including genomics, transcriptomics, metabonomics, proteomics, etc.).And combining the results with the drug reaction and clinical outcome of patients for a comprehensive analysis.The purpose of this study is to explore the potential biomarkers or omics of PD-1 therapy and lay the foundation for building a model to predict the effect of PD-1 therapy in patients with advanced pancreatic cancer.

  • Pancreatic Ductal Adenocarcinoma, PDAC
    • RJ2020368

    Study Record Dates

    These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

    Study Registration Dates Results Reporting Dates Study Record Updates

    2022-01-10  

    N/A  

    2022-01-24  

    2022-01-10  

    N/A  

    2022-02-08  

    2022-01-21  

    N/A  

    2022-01  

    Study Plan

    This section provides details of the study plan, including how the study is designed and what the study is measuring.

    Design Details

    Primary Purpose:
    N/A

    Allocation:
    N/A

    Interventional Model:
    N/A

    Masking:
    N/A

    Arms and Interventions

    Participant Group/ArmIntervention/Treatment
    Primary Outcome MeasuresMeasure DescriptionTime Frame
    The difference of progression free survival (PFS)The time from random to the first occurrence of disease progression or death from any cause.1.5 years
    Secondary Outcome MeasuresMeasure DescriptionTime Frame
    Disease control rate (DCR)The percentage of cases with remission and disease stability after treatment in the whole evaluable cases.1.5 years
    the quality of participants'lifeAccording to the European Organization for research and treatment of cancer (EORTC) quality of life core scale EORTC QLQ-C30 (V3.0 Chinese version)，evaluating the quality of life (QOL)1.5 years

    Contacts and Locations

    This section provides the contact details for those conducting the study, and information on where this study is being conducted.

    Study Contact

    Name: Yao Zhang

    Phone Number: 18019076695

    Email: zyrjxh97@sjtu.edu.cn

    Study Contact Backup

    Name: Duowu Zou

    Phone Number:

    Email:

    Participation Criteria

    Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

    Ages Eligible for Study:
    ALL

    Sexes Eligible for Study:
    18 Years

    Accepts Healthy Volunteers:

      Criteria:
      Inclusion Criteria:
      1. Age > 18 years old, male or female; 2. Locally advanced or metastatic pancreatic ductal adenocarcinoma confirmed by histopathology / cytology of the primary and / or metastatic lesions and unsuitable for surgical resection; 3. The failure of first-line chemotherapy with gemcitabine or FOLFINOX, disease progression or intolerable severe toxicity; 4. The time from the end of the last chemotherapy should be more than 28 days; 5. According to the evaluation criteria of solid tumor efficacy(RECIST 1.1), there should be at least one measurable lesion (non nodular lesion with the longest diameter of 210 mm, or nodular lesion with the shortest diameter of more than 15 mm); 6. ECOG score:0~2; 7. Hematology, biochemistry and organ function indexes meet the following requirements:

    • The absolute count of neutrophils (ANC) is more than 1.5x10% / L
    • Platelet count (PLT) ≥ 80x109/l
    • Hemoglobin (HB) ≥ 9.0 g/dl
    • TBIL is less than 2.0 ULN, albumin (ALB) 230g / L
    • In patients without liver metastasis, alanine transaminase (ALT) and / or aspartate -transaminase (AST) are less than 3.0 ULN
    • Patients with liver metastasis, ALT and / or ASTS <5.0*ULN
    • Serum creatinine (CREA) < 1.5 x ULN, and creatinine clearance rate (CER) ≥ 30ml / min (Cockcroft-Gault); 8. Women of childbearing age receives negative pregnancy test within 14 days before treatment. Male and female patients of childbearing age and their sexual partners agree to use reliable contraceptive methods within 14 days before enrollment, during the study and within 60 days after drug withdrawal； 9. Patients voluntarily participate in this study, sign informed consent, have good compliance, and cooperate with follow-up.

      • Exclusion Criteria:
      If any of the following criteria is met, the patient should be excluded:
      1. Pancreatic ductal adenocarcinoma is diagnosed without histopathology / cytology; 2. The target lesion has received local non-drug therapy (including radiotherapy, physical and / or chemical ablation, etc.), and there is no imaging progression; 3. If the central nervous system metastasis is known, MRI should be performed to exclude it; 4. Patients with carcinoma of Vater's ampulla or adenocarcinoma of biliary tract; 5. Patients with partial or complete intestinal obstruction or complete biliary obstruction that cannot be relieved by active treatment; 6. Ascites increases gradually after 2 weeks of conservative treatment (such as diuresis, sodium restriction, excluding ascites drainage); 7. In the past 5 years, patients had a history of other malignant tumors, except for the following two cases: a)After other malignant tumors treated by a single operation, 5-year disease-free survival (DFS) was achieved;b)Cured basal cell carcinoma of the skin and cured carcinoma in situ of the cervix; 8. Pregnant or lactating women; 9. Active infection; Poorly controlled hypertension (≥ 150 / 100mmhg); Angina pectoris and unstable angina pectoris in recent 3 months, myocardial infarction, cardiac insufficiency (> NYHA class II), schizophrenia, or history of psychotropic drug abuse in 1 year before enrollment; 10. If HBV-DNA is more than 104 copies or more than 2000 IU / ml, antiviral and liver protection therapy should be carried out first. Only when HBV-DNA is less than 104 copies (2000 IU / ml), can the patients be enrolled in the group, and continue to take antiviral drugs, monitor liver function and HBV viral load; HCV antibody or HCV-RNA were positive; HIV infected patients (non high risk group, without clinical symptoms or signs indicating HIV infection, HIV test may not be carried out); 11. Any of the following treatments were given within prior to enrollment:
      1. Within 4 weeks, received surgery of grade II or above (according to the operation classification catalogue (revised version in 2014) issued by the state health and Family Planning Commission); No matter whether it is related to tumor or not); 2. Received extended radiotherapy within 4 weeks or limited range radiotherapy within 2 weeks (researchers in each center can judge the appropriate time to enter the group according to the recovery of toxicity after radiotherapy); 3. Within 4 weeks or participating in other therapeutic / interventional clinical trials; 4. Received local anti-tumor therapy within 4 weeks; 12. NCI ctcae2 or above toxicity caused by previous treatment and not yet recovered (excluding hair loss and skin pigmentation); 13. It is known that PD-1 monoclonal antibody and its excipients are allergic or intolerable; 14. There are other situations that the researchers think are not suitable for inclusion in this study.

    Collaborators and Investigators

    This is where you will find people and organizations involved with this study.

      • PRINCIPAL_INVESTIGATOR: Duowu Zou, Ruijin Hospital

      Publications

      The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

      General Publications

      No publications available

      Treat yourself

      Let Us Take Care Of You

      BOOK AN APPOINTMENT ⟶
      footer logo

      About

      Events

      Fundraising

      Contact Us

      Facebook-f Instagram

      NPCF was founded on May 29, 2009 and is a 501(c)(3) organization. All donations are tax deductible.

      The information and services provided by the National Pancreatic Cancer Foundation are for informational purposes only. The information and services are not intended to be substitutes for professional medical advice, diagnosis or treatment. The National Pancreatic Cancer Foundation does not recommend nor endorse any specific physicians, products or treatments even though they may be mentioned on this site.

      Copyright © 2025 – National Pancreatic Cancer Foundation | All Rights Reserved

      Make-A-Will Month

      Snag 6508be92
      Learn More
      Donate Now Online
      Other Ways to Donate